Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A new tactic with ATR
December 2019
SHARING OPTIONS:

CAMBRIDGE, U.K., HOUSTON & SOUTH SAN FRANCISCO, Calif.—Last month saw the signing of a deal under which Artios Pharma Limited in-licensed a small-molecule ATR inhibitor program developed jointly by the University of Texas MD Anderson Cancer Center and ShangPharma Innovation. Per the agreement, Artios gains exclusive rights to research, develop, manufacture and commercialize resulting products globally. Financial details were not disclosed. The ATR inhibitor program results from a collaboration between ShangPharma and the MD Anderson Therapeutics Discovery team. The signaling protein ATR plays a role in DNA double-strand break repair and replication stress, and inhibiting ATR can make ATM-deficient tumors susceptible to destruction.
 
“Targeting DNA damage repair has the potential to provide an important therapeutic option for many patients in need of new treatments,” Dr. Philip Jones, vice president of Therapeutics Discovery at MD Anderson, commented in a news release. “We are pleased Artios will leverage its unique expertise in this field to advance this novel therapy toward the clinic to improve outcomes for cancer patients.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.